| 前收市價 | 13.31 |
| 開市 | 13.17 |
| 買盤 | 12.85 x 900 |
| 賣出價 | 12.87 x 900 |
| 今日波幅 | 12.84 - 13.22 |
| 52 週波幅 | 7.88 - 16.88 |
| 成交量 | |
| 平均成交量 | 4,155,979 |
| 市值 | 6.361B |
| Beta 值 (5 年，每月) | 1.30 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.50 |
| 業績公佈日 | 2024年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 17.75 |
Insider Monkey11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]
- Reuters
UPDATE 1-Elanco appoints two directors after settling with activist Ancora
Elanco Animal Health said on Monday that it had appointed two new directors to its board after reaching an agreement with activist investor Ancora Holdings but stopped short of naming a new CEO. The company that makes medicines and vaccinations for pets and livestock said it has added Kathy Turner and Craig Wallace to the board of directors. that it wanted four board seats at Elanco and to replace CEO Jeffrey Simmons over "poor performance."
- Reuters
Activist investor Ancora secures two Elanco board seats, Bloomberg News reports
Investment firm Ancora Holdings has reached an agreement with Elanco Animal Health to add two of its director candidates to the company's board, Bloomberg News reported late on Sunday, citing people with knowledge of the matter. Elanco, which makes medicines and vaccinations for pets and livestock will add Ancora nominees Craig Wallace and Kathy Turner to its board of directors, the report said. However, Elanco CEO Jeff Simmons will retain his position, the report added.
